Brexpiprazole is a novel D2 dopamine and serotonin 1A partial agonist, called serotonin-dopamine activity modulator (SDAM), and a potent antagonist of serotonin 2A receptors, noradrenergic alpha 1B and 2C receptors. Brexpiprazole is an atypical antipsychotic used in the treatment of schizophrenia and major depressivedisorders. In January 2018, it was approved .
SynZeal offers all Brexpiprazolerelatedimpurities standards with certified COA and characterization data like IR, Mass, HPLC, purity, NMR & TGA report. We also provide CMR, DEPT and detailed structure characterization report as per requirements. Brexpiprazolerelatedstandards are being used by major pharmaceuticalcompanies across the globe for their ANDA/DMF filing.
